focus -WSS

focus

author：leisure time 2025-09-29 19:59:12 - browse：98

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Stigma and the return of syphilis

WSS

FTX founder Sam Bankman

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Startling documents reveal new facets of Sacklers' opioid empire

Former Georgia lieutenant governor says he received grand jury subpoena

iTeos Therapeutics debuts first data on TIGIT

Dark money group runs ads on China biotech bill

focus

focus

Wikipedia

Sports medicine is finally prioritizing gender equality

Astronauts get first look at the spacecraft that will fly them around the moon

Bright Health sells Medicare Advantage business to Molina

Adam's Biotech Scorecard: Do Sarepta's exon

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biohaven protein

In Memoriam: Notable people who died in 2023

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Trump demands the U.S. pay no more for drugs than other countries … again

FTX founder Sam Bankman

knowledge

Prosthetic arm enables patients to feel the objects they grip

Stigma and the return of syphilis

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

AI used to predict Covid

iTeos Therapeutics debuts first data on TIGIT

focus

focus

leisure time

explore